Index

Note: Page numbers in italics refer to figures; page numbers in bold refer to tables.

Abacavir 323
Acetyl salicylic acid (ASA), see Aspirin
Action potential duration (APD)
  normal activity 28–9, 29, 48–50, 49
  prolonged 29, 29, 31, 51–2
  shortened 68
Acute lymphoblastic leukemia (ALL) 100, 107–8, 108, 114
Adults, cardiotoxic risks
  comorbidities 136–7, 242, 271
  predisposing factors 58, 67, 178, 275
  activity level and overweight 242
  smoking 276
AIDS, see Human immunodeficiency virus (HIV)
Alemtuzumab 137–8
Alkylating agents
  cardiotoxicity symptoms 129, 240
  dosage 105, 155–6
Allergy treatments, see Antihistamines, cardiotoxic risks
Alzheimer’s disease (AD) 293, 294–5
Angiotensin-converting enzyme (ACE) inhibitors 116
Animal testing
  anti-inflammatory drug development 262–3
  conditions for safety pharmacology trials 32, 33
  heart rate QT correction models 35–7
  investigation of drug synergies 240–1
  limitations 231, 238–9
  models for vascular effects of COXIBs 273
  spontaneously hypertensive rats (SHR) 239
  trastuzumab preclinical trials 244
Anthracyclines 99–103
  cardioprotective strategies 106–11, 109, 213–15, 223–4
  anthracycline analogs 133–6, 213–14, 231, 233–4, 245
  liposomal encapsulation 134–5, 215, 245
  manifestation of cardiotoxicity
    biopsy observations 206–7, 208
    clinical symptoms 38–9, 129, 212
    in myocardial cell types 236
    timing and progression 99–101, 131–3, 208–9, 212, 224–5
  risk factors 212–13, 213, 243
  age 102
  comorbidities 103, 215, 242
  cumulative dose 101–2
  genetic 229
  toxicity mechanisms 101, 102, 132, 204–5
  chemotherapeutic combinations 240–1, 241, 246–9, 247
  secondary alcohol metabolites 226, 229–30, 231, 233
  taxane/anthracycline interaction 231, 232
Antibiotics
  fluoroquinolones 71–3, 82
  macrolides 69–71, 81
  azithromycin 70–1
  erythromycin 69–71
Antidepressant drugs
  selective serotonine reuptake inhibitors (SSRIs) 63, 68
  tricyclic (TCAs) 63–4, 66
Antihistamines, cardiotoxic risks
  astemizole 56–9, 61, 75
  diphenhydramine (DPH) 58–9, 60
  hERG/IKr blockade, molecular mechanisms 59–61
  loratadine 60
  risk occurrence and predisposing factors 57–9
  terfenadine 56–7
Antimetabolites
  cardiotoxicity mechanisms 104, 152
  cardiotoxicity symptoms 129, 150–5, 240
Antimicrobial agents
  antibiotics (antibacterial) 69–73, 81, 82
  antifungals 73–4
  antiprotozoal drugs 74–6, 81
  antivirals 313–17
  clinical evidence of cardiotoxicity 68–9
Antioxidants 6, 226–7, 321
Antipsychotic drugs
  cardiac effect, action mechanisms 64–6, 68
  cardiotoxic risks 61–3, 64
Antiretroviral drugs 313, 314, 315
  non-nucleoside reverse transcriptase inhibitors (NNRTIs) 316
  nucleoside reverse transcriptase inhibitors (NRTIs) 315–16
  protease inhibitors (PIs) 316
Antitumor drugs
  agents classified by CT damage type 202–3, 203–4
  alkylating agents 129
    bendamustine 175
    cyclophosphamide 105, 155–6
    ifosfamide 156
  anthracyclines (and analogs) 99–103, 128, 129, 204, 210–11
  daunorubicin (DNR) 229
doxorubicin 100, 101, 105, 205–6
  epirubicin 133–4, 213–14, 230
  idarubicin 233
  mitoxantrone 103, 135, 214
  third generation formulations 135–6
antimetabolites 129
  capecitabine 153–4, 248
  cytarabine 151
  5-fluorouracil (5-FU) 104, 151–3
  gemcitabine 150–1
  histone deacetylase inhibitors (HDAC) 154–5
  aromatase inhibitors 179–80
  arsenic trioxide 130, 174–5
  cytokines 130
    interferon 172
    interleukins 172–3
  etoposide 175
  folate antagonists 130
    methotrexate 171
    pemetrexed 171
  5-hydroxytryptamine3 receptor antagonists 180
  immunomodulating agents 130
    lenalidomide 161
    pomalidomide 161
    thalidomide 160–1
  microtubule-targeting drugs 129–30
    epilithones 159
    taxanes 158–9, 231
    vinca alkaloids 157
    vinflunine 158
  monoclonal antibodies 129
    alemtuzumab 137–8
    bevacizumab 147–9
    cetuximab 137
    lapatinib 146–7, 247–8
    rituximab 136–7
    trastuzumab 105–6, 139–46, 215–16, 243
  platinum-based 130
    cisplatin 168–70
    satraplatin 171
  proteosome inhibitors 130
    bortezomib 166–8
    second-generation agents 168
  radioimmunotherapy 130
    gemtuzumab ozogamicin 174
    ibritumomab tiuxetan 174
    tositumomab 174
INDEX

retinoids 130
  bexarotene 166
tamoxifen 130, 179–80
tyrosine kinase inhibitors (TKI) 130
  erlotinib 165
  gefitinib 165
  imatinib 162–3, 249
  sorafenib 164, 248
  sunitinib 163, 248
see also under individual drugs and drug classes
APPROVE trial (colon polyps and rofecoxib) 268, 269, 301–2
Arachidonic acid (prostaglandin substrate) 259, 260, 261, 274
role in apoptosis 9
  shunt, to LOX pathway 276
Aromatase inhibitors 179–80
Arrhythmia, cardiac
  antiarrhythmic drugs 30
  biomarkers 61
drug effect mechanisms 52
  genetically-determined 29–30, 30, 53, 66–7
  QT prolongation 29, 29–31, 49, 51–2, 59
torsade de pointes (TdP) 28, 49, 51–2
Arsenic trioxide, adverse effects 130, 174–5
Arthritis, anti-inflammatory trials 264–6, 270, 292–3
Aspirin
  and colon cancer mortality 267
discovery and structure 258, 259
dynamic interaction with other NSAIDs 304–6
effect on platelet prostaglandin levels 277, 288, 290
  reduction of heart attack risk 288–9
  observational studies 296
Astemizole 56–9, 61, 75
Atherosclerosis 101, 115, 170, 177–8, 320–2
ATP synthesis 2
  response to oxidative stress 3–4
  uncoupling, by protonophores 12–13
Azithromycin 70–1
Azole antifungal agents 73–4
Bazett’s formula 31, 34–5
Bendamustine 175
Beta-blockers 110, 116–17
Bevacizumab 147–9
Bexarotene 166
Biomarkers, cardiac
  highly sensitive C-reactive protein (hsCRP) 115
  natriuretic peptides 113, 115, 218–19, 241
Biopsy
  grading of structural abnormalities 206–7, 207, 209
  myocardial damage appearance 153, 162, 208
Bone marrow transplantation (BMT), cardiac complications
  atherosclerosis and hypertension 177–8
  conditioning and early risks 175–7
graft versus host disease (GVHD) 178
  later heart failure 177
Bortezomib 166–8
Brain natriuretic protein (BNP) 113, 218–19
Breast cancer
  adjuvant treatment 132, 142–3, 145–6, 159, 225
cardioprotective use of dexrazoxane 107
  chemotherapy, synergistic effects 105–6, 216, 243–7
  metastatic (MBC) 139–41, 143–4
treatment effects on lipid metabolism 179–80
Brugada syndrome (BrS) 66–8, 67
Bupivacaine, cardiac toxicity 11
Calcium
  dysregulation, by anthracycline derivatives 226, 240–1
  interaction with effects of ROS 7, 8, 9
  intracellular Ca^{2+} flow in ischemia 5–6
  membrane channels 33, 50
  blockers, cardioprotectant 117
Calpains 9–10
Cancer
  cardioprotective strategies 106–11, 109
  continuous infusion 107, 214
drug analog development 133–6, 213–14, 231, 233–4, 245
Cancer (Continued)
molecular delivery systems 215, 237
protective agents 106–11, 214
standard heart failure treatments 115–16
cardiotoxicity (CT) risks 127–8, 201, 202–3
additive 102, 105–6, 139–40, 238
diagnosis 202, 204, 216, 216–17
incidence 39, 127–8, 131–3, 223–4
long-term/delayed 98–9, 118, 132–3, 224–5, 238
symptoms and mechanisms 99–105, 128, 129–30, 224
monitoring, cardiovascular
biopsy 153, 162, 206–7
echocardiography 111–12, 217–18
markers, cardiac 112–15, 218–19, 241
multigated cardiac blood pool (MUGA) scans 218
prevention, by anti-inflammatory treatment 267–71, 279
see also Antitumor drugs
Capecitabine 153–4, 248
Carbonyl reductase (CBR) polymorphism 229–30
Cardiolipin 7, 8, 11, 13, 101
Cardioprotective agents 109
ACE inhibitors 116
anesthetics 16
beta-blockers 110, 116–17
calcium channel blockers 117
dexrazoxane 107–9, 108, 214, 226–7
metabolic supplements 110–11, 226
Cardiovascular malfunctions 26, 26–7
acute myocardial infarction (AMI) 288–9, 291, 322–3
arrhythmias 31, 51–2, 169
atherosclerosis 101, 115, 170, 177–8, 320–2
blood pressure disorders (hyper/hypotension) 148, 163–5, 177–8, 203
cardiomyopathy 100–1, 203–5, 215, 226, 319–20
chest pain 152–4, 157–8
ischemia 2–3, 203, 240–1
thromboembolisms 148–9, 160–1
Carnitine 5, 14–15, 110
Carvedilol 110, 226
Celecoxib
clinical trials, osteoarthritis patients 264–6, 267, 274
colon cancer prevention and CT risks 268–71, 269
combined with chemotherapy in lung cancer 279
development 263, 264
Cetuximab 137
Childhood cancer
cardiac damage, causes and assessment 99–105, 106, 111–15
chemotherapy, long-term effects 98–9, 118, 225, 236
incidence and survival 97, 99
survivors, follow-up treatment 111, 115–17
Chloroquine 75
Cisplatin 168–70
CLASS osteoarthritis trials 264–6, 274, 293
Coenzyme A (CoA), acyl/free ratio 14–15
Coenzyme Q10 110–11
Colon polyps and cancer 267–71, 293–4
Complementary treatments 110
Congestive heart failure (CHF), see Heart failure (HF)
Continuous infusion 107, 214
Coronary artery bypass graft (CABG) patients 270–1
COX-2 selective inhibitors (COXIBs)
Alzheimer’s disease, risk reduction 293, 294–5
cancer chemoprevention 267–71, 279, 293–4
cardiovascular side effects 270–8, 288, 290–1
additional effect of low nitric oxide 275
leukotriene products in smokers 276
prostaglandin suppression 272–4
raised tissue factor synthesis 275
signaling cascade responses 275–6
comparison trials with NSAIDs 264–6, 266, 267, 277–8, 288
discovery and development 263, 264
Cyclooxygenase (COX) enzyme active sites, structure and action mechanisms 259, 260, 263, 265
Data collection on adverse events of anti-HIV drugs (DAD) 319, 322–3
Databases, for epidemiological analyses 297, 300–1
Dexrazoxane 107–9, 108, 214
Diabetes mellitus drug treatment 39–40
Diclofenac 258, 263, 265–6, 267
long-term use, cardiovascular risk 270, 270, 274, 277, 293
Diphenhydramine (DPH) 58–9, 60
Doxorubicin (DOX) 100, 101, 105, 205–6
doxorubicinol metabolite (DOXOL) 205, 226, 227, 227–8
toxicity mechanism 13, 14–15
tumor-targeted formulations 135, 215
Drug administration, see Treatment protocols
Drug development
clinical trials 139–40, 291–5
drug toxicity comparisons 264–6
ICH E14 guideline 27, 31, 33
patient entry criteria 224, 245–6, 303–4
observational studies 292, 295–7, 298–9, 305–6
pharmacology safety studies 26, 27–38
integrated risk assessment 32, 32–3
post-authorization trials 292–3
meta-analysis 295, 297, 300, 300–1
preclinical screening 83–4, 224
animal models 32, 33, 39, 239–41, 244
assay applicability 274
test dose/concentration 33–4
translated human heart models 33, 228–38
regulatory agencies 25–6, 47–8, 231
published guidelines 27, 28, 30–5, 38, 40
reporting adverse events 127–8, 167
anti-HIV drugs (DAD) study 319, 322–3
assessment endpoints 26, 27
simulation of multiple-hit mechanisms 238, 239–40, 242, 243, 246–9
toxicology studies 26, 27, 38–40
withdrawal from market proportion due to cardiovascular risks 25
specific examples 58, 61, 62, 72, 257
Drugs, noncardiovascular
antihistamines 56–61
antimicrobial agents 68–76
antineoplastics, see Antitumor drugs antiretrovirals 313–17
psychotropic agents 61–8
Echocardiography 111–12, 217–18
Electrocardiograms (ECGs) 49, 50–1
in acute anthracycline cardiotoxicity 131
and chest pain, with antimetabolites 150–5
correction for heart rate dependence ANCOVA model 35–7, 36, 37
formulae 34–5, 36
QT/RR analysis 37, 37–8
parameters, for clinical studies 31–2
see also Action potential duration (APD)
Electron transfer chain (ETC) 2
alternate electron acceptors 13
chemical inhibitors 10–12
inhibition, through oxidative stress 3–5, 4, 7
Enalapril 116
Endothelial cells, heart tissue 236, 321
Epidermal growth factor receptor (EGFR) TKIs
adverse side-effects 130, 165
overexpression, in breast cancer 139
Epilithones 159
  cardiotoxicity symptoms 130
Epirubicin (EPI) 133–4, 213–14
  EPIOL aglycone formation 234, 235
  epirubicinol metabolite (EPIOL) 226, 230
toxicity, compared with doxorubicin 230, 233, 245
Erlotinib 165
Erythromycin 69–71, 81
Etoposide 175
Etoricoxib 264, 270, 270, 277, 293
Fibroblasts, heart tissue 236
Fluoroquinolone antibiotics 71–3, 82
5-fluorouracil (5-FU) 104, 151–3
Folate antagonists, cardiotoxicity symptoms 130, 171
Fredericia’s formula 34, 35
Free radicals
  membrane damage 205
  sources, from anthracycline treatment 13, 226
Fungal infections, drug therapy risks 73–4
Gastrointestinal (GI) toxicity
  comparison of tNSAIDs and COXIBs 264–6, 266, 267
  NSAID-sensitive patients 257, 261–2
  risks and mitigation 287–8
  studies in animal models 262–3
GATA-4 transcription factor 205
Gefitinib 165
Gemcitabine 150–1
Gemtuzumab ozogamicin 174
Good laboratory practice (GLP) compliance 34
Graft versus host disease (GVHD) 178
Growth hormone 117–18
Halofantrine 75–6, 81
Heart failure (HF)
  assessment criteria 128, 206
  in childhood cancer patients 99, 106, 116
  long-term risks 39, 132–3, 224–5, 238
Hepatitis B virus (HBV) 313
co-infection with HIV 314
hERG (human ether-a-gogo-related gene product)

Iₖr function blockade
  by antihistamines 59–61
  by antipsychotic drugs 64–6
  molecular mechanisms 80–3
  molecular structure, K channels 77–9, 78
  relationship to QT interval 30
  voltage dependence 53–6, 55
Highly active antiretroviral therapy (HAART) 313
  clinical recommendations 316–17, 317
  side effects 314, 317, 319, 320, 322
Highly sensitive C-reactive protein (hsCRP) 115
Histone deacetylase inhibitors (HDAC) 154–5
Human immunodeficiency virus (HIV) 313
  AIDS incidence 314
  antiretroviral therapy strategies 314, 315, 316–17, 317
  associated cardiovascular disease 319
Hydrogen peroxide, see Reactive oxygen species (ROS)
5-hydroxytryptamine₃ receptor antagonists 180
Hypertension
  after bone marrow transplants 177–8
  incidence, with receptor TKIs 163–5
  induced by bevacizumab 148
  induced by drugs 27
Hypocalcemia 74
Hypokalemia 58
Hypomagnesemia 58
Ibritumomab tiuxetan 174
Ibuprofen 265, 266, 267, 304–6
Ifosfamide 156
Imatinib 162–3, 249
Immunomodulating agents, cardiotoxicity symptoms 130, 160–1
Inner mitochondrial membrane (IMM)
  electrochemical potential gradient 2, 4
  permeability transition pore 3, 8–10
  proton permeability 12–13
Insulin 321–2
Interferon 172
Interleukins 172–3
International Conference on Harmonization (ICH) guidelines 31–5
Iron homeostasis dysregulation 226
Ischemia 2–3, 203, 240–1
ischemic preconditioning (IPC) 15–16

K channels, see Potassium channels, membrane

Lactic acidosis 5, 9
Lapatinib 146–7, 247–8
Left ventricular (LV) dysfunction caused by anthracyclines 100–1, 240–1
delayed repolarization 27
ejection fraction (LVEF), reduced 110, 117, 128, 217
Lenalidomide 161
Liposomal encapsulation 134–5, 215, 245
5-lipoxygenase (5-LO) enzyme 276
Long QT syndrome (LQTS) 29–30, 30, 53, 67
Loratadine 60
Lung cancer, non-small-cell (NSCLC) 279

Macrolide antibiotics 69–71, 81
Malaria, drug therapy risks chloroquine 75
halofantrine 75–6, 81
quinine 74–5
MEDAL long-term arthritis trial 270, 270, 277, 293
Membrane repolarization 48–50
currents, components 28
currents (I\text{k}), components 52–3
K channel structure 77–9, 78
Methanesulfonanilides 53, 79, 80
Methotrexate 171
Microsomal prostaglandin E\textsubscript{2} synthase (mPGES) inhibitors 276
Microtubule-targeting drugs
cardiotoxicity symptoms 129–30, 157–9
sources and action 157, 158
Mitochondria
cell injury involvement 15–16, 16
ETC inhibition 10–12
metabolic pathway inhibition 14–15
redox cycling 13
uncoupling of ATP synthesis 12–13
hydrogen peroxide (H\textsubscript{2}O\textsubscript{2}) formation 7
inner membrane functions 2
mtDNA damage mechanisms by anthracyclines 205
by NRTI antiviral agents 317–19
Mitoptosis 319
Mitoxantrone 103–4, 135, 214
Models, human heart
animal models integrated multiple-hit models 242, 243, 246–7, 247
multiagent cardiotoxicity 240–1, 241
murine preclinical trials 32, 239, 244
translational (myocardial strips) tests of viability 228
toxokinetic simulations 228–34, 236
uses and limitations 235–8
Monitoring, cardiovascular
cardiography 34–8, 111–12, 128, 217–18
cell damage biopsy 153, 162, 206–7, 320
chemical biomarkers 111–15, 218–19, 241
regulatory guidelines 28, 31–2, 40
Monoamine oxidases (MAO) 7
Monoclonal antibodies
drug interactions 106, 139–43, 216, 243–4
side-effects of treatment 129, 136–40, 146–9, 216, 245
Multigated cardiac blood pool (MUGA) scans 218
Multiple-hit cardiotoxicity 238, 239–40, 242, 243, 246–7
Myocardial infarction (MI) 288–9, 291, 322–3
Myocardium
adaptive hypertrophy 14, 100, 204, 209, 236
cell types in myocardial tissue 236
damage, in atherosclerosis 321
consequences of ischemia 2–3
permanent damage and cumulative dose 205–6, 206, 209
reversible damage 215–16
see also Models, human heart
Myocytes
  cell death mechanisms 3, 8–10, 14–15
damage imaging (biopsy) 206–7,
  207, 208
ultrastructural 320
electrical activity phases 28–9, 29, 50
mechanisms of toxicity 1, 4, 162
anthracycline damage 100–1, 102,
  204–5, 226
bupivacaine 11
doxorubicinol accumulation
  228, 229
reductases, activity 229–30
oxygen supply dependence 2, 3
Nanoparticle drug delivery 159, 237
Naproxen 265, 277–8, 288–9, 304
Natriuretic peptides 113–15, 218–19, 241
Nitric oxide (NO)
biosynthesis 275
metabolic damage mechanism 6
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 316
Non-steroidal anti-inflammatory drugs (NSAIDs)
cardiovascular risk assessment 291–301
drug interactions 304–6
effects of exposure duration 301–4
observational studies 296–7, 298–9
comparison trials with COXIBs 264–6, 266, 267, 277–8, 288
competitive inhibition of COX,
  mechanism 258–9, 260, 290
GI toxicity reduction 262–3, 287–8
history of development 257–8
side-effects of use 261–2, 288
structures, traditional NSAIDs 259
Nucleoside reverse transcriptase inhibitors (NRTIs)
antiviral action mechanism 315–16
cardiomyopathy 319–20
heart failure and MI 322–3
mitochondrial toxicity 317–19
Nucleotide pool imbalance,
  mitochondrial 318–19
Nucleotide reverse transcriptase inhibitors (NtRTIs) 316
Over-the-counter (OTC) drug use 58–9, 296
Oxidative phosphorylation, see ATP synthesis
Oxidative stress 205
anaerobic glycolysis reactions 4–5
ATP synthesis and hydrolysis 3–4
effects on intracellular Ca$^{2+}$ 5–6
ischemic preconditioning 15–16
PTP opening 8, 8–10
sources of ROS 6–7
Paclitaxel (PTX) 158–9, 231, 237
Pegylation 134–5, 215
Pentamidine 76
Peroxisome proliferator-activated receptor (PPAR) agonists 40
Phenylbutazone 258, 259
as scaffold for diarylheterocycle COXIBs 263, 264
Phosphate, inorganic (Pi) 9
Platelets
  activating factor (PAF), and antihistamines 59
  aggregation control 272, 288, 304
  aspirin blockade 290
  growth factor receptor, and TKIs 162, 163
Platinum chemotherapy drugs
cardiotoxicity symptoms 130, 168–9
long-term risks 169–70
Polymerase γ (pol-γ) inhibition 318
Polyposis, familial 271, 279
Pomalidomide 161
Potassium channels, membrane
  molecular basis of drug binding 80–3
  structure and selectivity, hERG channels 77–8, 78, 82
  voltage-sensing domain (VSD) 78–9
Progenitor cells, cardiovascular 236–7
Prostacyclin (PGI$_2$) 271–4, 290–1
Prostaglandin H synthase, see Cyclooxygenase (COX) enzyme
Prostaglandins
  microsomal E$_2$ synthases (mPGES), inhibition 276
  physiological roles 272, 272, 290–1
suppression by COXIBs 272–4
synthesis 259–61, 260, 261
Protease inhibitors (PIs)
antiviral action mechanism 316
risk of side-effects
atherosclerosis 320–2
myocardial infarction 322
Proteosome inhibitors
possible cardiotoxicity symptoms 130
reports of adverse effects 166–8
Proton motive force (Δp) 2
monitoring techniques 11–12
role in mitochondrial Ca²⁺ flow 5–6
Protozoal parasites, drug therapy risks
antimalarial drugs 74–6, 81
pentamidine 76
Psychoactive drugs, cardiovascular side-effects
antidepressants 63–4, 66, 68
antipsychotics 61–3, 64–6, 68
Brugada syndrome (BrS) 66–8, 67
hERG/IKᵣ inhibition 64–6
Purkinje fibers
electrical activity sequence 48–50
use in clinical studies 31
QT interval, prolonged, see Arrhythmia, cardiac; Long QT syndrome (LQTS)
Quinine 74–5
Radioimmunotherapy
adverse effects 130, 174
therapeutic role 173
Radiotherapy risks 106
Reactive oxygen species (ROS)
antiviral-induced overproduction 319, 321
generation, from activated anthracyclines 226–7, 227
toxicity and cardiac function 6–7, 8, 11
Reductases, cytoplasmic 227–8, 229–30
Respiratory oxidation, see Electron transfer chain (ETC)
Retinoids, adverse effects 130, 166
Rituximab 136–7
Rofecoxib
cardiovascular events in colon polyp trial 268, 269
clinical trials, rheumatoid arthritis patients 264–6, 266, 288
development 263, 264
Satraplatin 171
S7B guideline (QT prolongation testing) 31–5
Selective serotinine reuptake inhibitors (SSRIs) 63, 68
Serum biomarkers, see Biomarkers, cardiac
Signaling pathways, cardiovascular 7, 9–10, 244–5, 275–6
Sodium, role in cell depolarization 28, 48–9, 50
Sorafenib 164, 248
Spontaneously hypertensive rats (SHR) 239
Sulindac 271, 279
Sunitinib 163, 248
Superoxide anion, see Reactive oxygen species (ROS)
Tamoxifen
cardiotoxicity symptoms 130
effect on lipid metabolism 179–80
TARGET osteoarthritis trials 293
Targeted drugs, see Monoclonal antibodies; Tyrosine kinase inhibitors (TKI)
Taxanes
cardiotoxicity symptoms 129, 158–9
interaction with anthracyclines 231, 232
paclitaxel 158–9, 237
Tenofovir disoproxyl fumarate (TDF) 316, 317
Terfenadine 28, 56–7, 80
Thalidomide 160–1
Thiazolidinediones 39–40, 322
Thromboembolisms
deep venous 160–1
mechanisms of COXIB effects 272–6
risk, with monoclonal antibody treatment 148–9
Thromboxane (TxA₂) 273, 277, 289, 290, 304
Torsade de pointes (Tdp)
description 49, 51
incidence 28, 52
risk classification of drugs 64
Tositumomab 174
Transmembrane receptor inhibitors 161–5
<table>
<thead>
<tr>
<th>Index Entry</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trastuzumab</td>
<td>215–16, 243</td>
</tr>
<tr>
<td>breast cancer patients, clinical trials</td>
<td>105, 139–46</td>
</tr>
<tr>
<td>mechanism of synergism with anthracyclines</td>
<td>244–5</td>
</tr>
<tr>
<td>multiple-hit risk factors</td>
<td>246–7, 247</td>
</tr>
<tr>
<td>preclinical screening</td>
<td>244</td>
</tr>
<tr>
<td>Treatment protocols</td>
<td></td>
</tr>
<tr>
<td>administration method</td>
<td>239</td>
</tr>
<tr>
<td>continuous infusion</td>
<td>107, 214</td>
</tr>
<tr>
<td>cumulative load</td>
<td>132, 155–6, 205–6, 206</td>
</tr>
<tr>
<td>dose effects</td>
<td>101–2, 105, 133–4</td>
</tr>
<tr>
<td>multiple therapies, synergistic effects</td>
<td>102–3, 105, 139–40, 153, 169</td>
</tr>
<tr>
<td>patient use of complementary treatments</td>
<td>110</td>
</tr>
<tr>
<td>sequential multiple delivery</td>
<td>245, 304–6</td>
</tr>
<tr>
<td>Tricyclic antidepressants (TCAs)</td>
<td>63–4, 66</td>
</tr>
<tr>
<td>Troponins</td>
<td>112–13, 219</td>
</tr>
<tr>
<td>cardiac troponin I (TnI)</td>
<td>239</td>
</tr>
<tr>
<td>cardiac troponin T (TnT)</td>
<td>108, 108</td>
</tr>
<tr>
<td>Tyrosine kinase inhibitors (TKI)</td>
<td></td>
</tr>
<tr>
<td>cardiotoxicity symptoms</td>
<td>130, 162–5</td>
</tr>
<tr>
<td>clinical trials</td>
<td>247–9</td>
</tr>
<tr>
<td>Ultrasound, cardiac, see Echocardiography</td>
<td></td>
</tr>
<tr>
<td>Vascular endothelial growth factor (VEGF)</td>
<td></td>
</tr>
<tr>
<td>bevacizumab therapy</td>
<td>147–8</td>
</tr>
<tr>
<td>new anti-VEGF agents</td>
<td>150</td>
</tr>
<tr>
<td>Vascular smooth muscle cells (VSMC)</td>
<td>321</td>
</tr>
<tr>
<td>Ventricular tachycardia, polymorphic, see Torsade de pointes (TdP)</td>
<td></td>
</tr>
<tr>
<td>VIGOR rheumatoid arthritis trials</td>
<td>264–6, 266, 268, 288, 292–3</td>
</tr>
<tr>
<td>Vinca alkaloids</td>
<td>157</td>
</tr>
<tr>
<td>Vinflunine</td>
<td>158</td>
</tr>
<tr>
<td>Vitamin E supplementation</td>
<td>226</td>
</tr>
<tr>
<td>Zidovudine (AZT)</td>
<td>317–18, 320</td>
</tr>
</tbody>
</table>